## Otterbein University

# Digital Commons @ Otterbein

Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

Fall 2014

# Malignant Hyperthermia

Eric Weberding Otterbein University, eric.weberding@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu\_msn

Part of the Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Medical Pathology Commons, Musculoskeletal Diseases Commons, and the Nursing Commons

#### **Recommended Citation**

Weberding, Eric, "Malignant Hyperthermia" (2014). *Nursing Student Class Projects (Formerly MSN)*. 20. https://digitalcommons.otterbein.edu/stu\_msn/20

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an authorized administrator of Digital Commons @ Otterbein. For more information, please contact digitalcommons07@otterbein.edu.

# **Malignant Hyperthermia**

Eric D. Weberding BSN, RN Otterbein University, Westerville, Ohio

#### Definition

Malignant hyperthermia (MH) is an autosomal-dominant disorder that is inherited. The disturbance of calcium homeostasis associated with MH affects skeletal muscle (Schneiderbanger, Johannsen, Roewer, & Schuster, 2014). This hypermetabolic muscular disorder is triggered by exposure to depolarizing muscle relaxants such as succinvlcholine or inhaled halogenated volatile anesthetics such as sevoflurane, halothane, desflurane, enflurane, and isoflurane (Stratman, Flynn, & Hatton, 2009). In susceptible individuals, this potentially ethal syndrome may cause hyperthermia, hypercapnia, muscular rigidity, hypoxemia, acidosis, tachycardia, and hyperkalemia (Schneiderbanger et al., 2014).

#### Relevance

MH occurs more often in children and young adults than in the adult population. MH occurs more often in adult males than adult females. Distribution across ethnicities occurs in equal proportions (Stratman et al., 2009). While a link between MH and numerous myopathies is suspected, a predisposition has only been identified in Evans myopathy, central-core disease, and King-Denborough syndrome (Stratman et al., 2009).

Although MH is a rare inherited disorder, this potentially life-threatening inherited disorder may occur approximately once in every 3,000 procedures involving general anesthesia (Beggs, McCann, & Powers, 2012), While obtaining thorough patient and family histories related to anesthesia events will reduce occurrences of MH, many individuals are unaware of their own predisposition to this disorder and relevant family histories. More efficient treatment of MH and improved understanding of the pathophysiology related to this disorder have resulted in an 11.7% decline in the mortality rate from MH from 2000 to 2005 Johns, Stoudt, Scholtis, & Gavel, 2012).

However, to further improve outcomes for patients with malignant hyperthermia, it is imperative for multidisciplinary medical team members to promptly recognize early symptoms of MH, accurately diagnose this disorder. and respond swiftly with the appropriate treatment (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013).



### **Underlying Pathophysiology**

Individuals with MH have a mutation of the ryanodine receptor subtype 1 (RYR1) gene on chromosome 19q 13.1-13.2 (Li, Brady, Rosenberg, & Sun, 2011; Thomas & Crowhurst, 2013). When the dysfunctional receptor is exposed to triggering agents, such as halogenated volatile anesthetics and succinvlcholine, a depolarizing neuromuscular blocking agent, the prolonged opening of this dysfunctional receptor occurs and results in the uncontrolled release of calcium within the skeletal muscle sarcoplasmic reticulum causing a hypermetabolic state in the susceptible individual (Kim, 2012).

As a result of this uncontrolled release of calcium and continuous muscle activation, muscle rigidity occurs. As these events continue, cellular adenosine triphosphate is depleted resulting in protracted muscular rigidity and eventually rhabdomyolysis, Rhabdomyolysis occurs when cell contents such as creatine phosphokinase, potassium, and myoglobin are released into circulation due to the deterioration of the cell membrane. Also, in a MH event, oxygen consumption is increased due to the continuous activation of aerobic and anaerobic metabolism. This increase in oxygen consumption results in acidosis, hypoxia, increased body temperature, and excessive production of CO<sub>2</sub> (Schneiderbanger et al., 2014). Figure 1 illustrates the pathophysiological changes that occur during a malignant hyperthermia event.



### Significance of Pathophysiology

#### The following physiologic manifestations are linked to MH:

1. Muscular rigidity most often involving the masseter: results from the uncontrolled and ongoing release of calcium from the sarcoplasmic reticulum (Schuster, Johannsen, Schneiderbanger, & Roewer, 2013). 2. Hyperthermia: results from the increased use of adenosine triphosphate combined with the constricting peripheral vasculature. The body's ability to dissipate heat is markedly impaired (Schneiderbanger et al., 2014).

3. Increased ETCO2: results from an increase in myoplasmic calmodulin-dependent protein kinase (Ca2+). An unexplained increase in ETCO<sub>2</sub> is a common and early sign of MH in mechanically ventilated and intubated patients (Kim, 2012).

4. Acidosis: respiratory acidosis results from increased CO2 levels. Metabolic acidosis results from increased lactate levels (Dirksen et al., 2013).

5. *Myoglobinuria*: results from damage to the cell membrane allowing intracellular contents, such as magnesium, potassium, creatine, and myoglobin to seep into the bloodstream (Dirksen et al., 2013). 6. Renal Failure: due to cell membrane damage, released myoglobin obstructs renal tubules causing acute renal failure (Kim, 2012).

7. Tachycardia/tachypnea: Excessive amounts of CO<sub>2</sub> (hypercarbia) and excessive K (hyperkalemia) in the blood stimulate the sympathetic nervous system resulting in rapid heart rate and/or rapid breathing (Dirksen et al., 2013).

8. Cardiac arrhythmias/failure: Potentially fatal dysrhythmias occur due to hyperkalemia and the kidneys inability to excrete excess K (Dirksen et al., 2013).

## **Implications for Nursing Care**

- ✓ MH treatment objectives: stop the abnormal metabolic reaction with dantrolene and restore normal hemodynamic conditions, temperatures, and metabolic functions. (Seifert, Wahr, Pace, Cochrane, Bagnola, 2014)
- Recommended management approach: Utilize a ~ multidisciplinary medical team trained to promptly and accurately diagnose MH, work cooperatively, understand multiple roles and responsibilities, and efficiently utilize readily available equipment and medications; medical teams should periodically review MH protocol and participate in mock drills to practice tasks and roles (Dirksen, 2013)
- See Figure 2 for recommended roles and treatment

### **Implications for Nursing Care**

#### Figure 2 Personnel roles and treatment interventions in a MH event (Seifert et al., 2014, p. 197)

#### Crisis Considerations: Malignant Hyperthermia 28 AOR N

				TION
PREOPERATIVE PHASE: PATIENT ASSESSMENT Metally raise for maniputant hyporthermits (MH) hyportan advances on the second and an advances of MI, hyportan advances or unsuitan effection. We associated anotherios - Tanking methor with or operiorized MH ar a three-relative a hyportant thready methods and schwardiane - Neisenian thready methods and schwardiane - Neisenian thready methods and schwardiane - Stephenian and schwardiane and schwardiane - Stepheniane and schwardiane and schward and schward - Stepheniane and schward and schward and schward and schward - Stepheniane and schward and schward and schward and schward - Stepheniane and schward and schward and schward and schward - Stepheniane and schward and schward and schward and schward - Stepheniane and schward and schward and schward and schward - Stepheniane and schward and sch		INTRAOPERATIVE PHASE: PATIENT SAFETY All team members participate in the surgical time out and address team of the surgical time out and address team for the surgical surgical surgical surgical surgical surgical Between yook and states Between yook and yook and yook and yook and yook Between yook yook and yook and yook and yook and yook and Between yook yook and yook and yook and yook and yook and Between yook yook and yook and yook and yook and yook and Defermine in advances who the leader will be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should an MH circles accur- tion should not provide the should be should be should an MH circles accur- tion should not provide the should be should b		
Is an MH crisis	s occurring?	(ie, should h	ot be the surgeon, KN circulati	or, or anestnesia professional)
	What is the management	plan? Who wi	Call for help and obt (May be performed by any mem	ain the MH cart ber of the sargical team)
/	what is the management			
SURGEON/ SURGICAL ASSISTANT Terminate the procedure, if possible	ANESTHESIA PROFESSIONAL Request MH medications Stop volatile, inhalational anesth Do not delay treatment to char anesthesia circuit or carbon di	netics age the oxide absorber	RN CIRCULATOR Call for help	SCRUB PERSON Be prepared to assist with lavaging body cavities
Cost the patient by including seen body contrasting that room-temperature aline in the pertoneum) If possible, break scrub to assist with insorting tables into ortices (e.g. ans. author) for langue (e.g. au	Is it time for the MH leader Administer MH drugs A segment in the segment of the segment and the segment of the segment of the segment - input demotions - input	to activate the Mobility addition of the second second second of the second second second second of the second second second second second of the second second second second second of the second second second second second second of the second second second second second second of the second second second second second second second second second second second second second second of the second sec	MH crisis protocol? If and personal and the personal an	Assist with childed brougs of internal brougs of internal operations of the second operation of the second operation of the second operation of the second operation of the second Martinian an organized Martinian an organized

#### **Conclusions**

The ultimate goal is to prevent the occurrence of MH. As discussed by Beggs, McCann, and Powers (2012), prior to the administration of anesthesia, obtaining thorough patient and family histories related to adverse anesthesia reactions may alert the anesthesia provider to the patient's possible predisposition to MH and dictate the selection of non-triggering MH anesthesia agents. However, when prevention is not realized, continued vigilance and crisis preparedness on the part of multidisciplinary medical team members will further reduce the MH mortality rate and improve patient outcomes (Schneiderbanger et al., 2014).

## References

Beggs, A. E., McCann, J., & Powers, J. M. (2012). Delayed-onset malignant hyperthermia in association with rocuronium use. American Journal of Health-System Pharmacy, 69(13), 1128-1134. doi:10.2146/aihp110306 Dirksen, S., Van Wicklin, S. A., Mashman, D., Neiderer, P., & Merritt, D. (2013). Developing effective drills in reparation for a malignant hyperthermia crisis. AORN Journal, 97(3), 330-352, doi:10.1016/j.aorn.2012.12.009 Johns, C., Stoudt, R., Scholtis, M., & Gavel, T. (2012). Malignant hyperthermia: a crisis response plan. OR Manager, 2(6), 18-21. Kim, D. (2012), Malignant hyperthermia. Korean Journal of Anesthesiology, 63(5), 391-401. doi:10.4097/kjae.2012.63.5.391 Li, G., Brady, J., Rosenberg, H., & Sun, L. (2011). Excess comorbidities associated with malignant hyperthermia. Paediatric Anaesthesia, 21(9), 958-963. doi:10.1111/j.1460-9592.2011.03649.x Schneiderbanger, D., Johannsen, S., Roewer, N., & Schuster, F. (2014), Management of malignant hyperthermia. Therapeutics & Clinical Risk Management, 10355-362. doi:10.2147/TCRM.S47632 Schuster, F., Johannsen, S., Schneiderbanger, D., & Roewer, N. (2013). Evaluation of suspected malignant hyperthermia. BMC Anesthesiology, 13(1), 24-30. doi:10.1186/1471-2253-13-24 Seifert, P. C., Wahr, J. A., Pace, M., Cochrane, A. B., & Bagnola, A. J. (2014). Crisis Management of Malignant Hyperthermia in the OR. AORN Journal, 100(2), 189-202.e1. doi:10.1016/j.aorn.2014.06.014 Stratman, R., Flynn, J., & Hatton, K. (2009). Malignant hyperthermia. Orthopedics, 32(11), 835-838. doi:10.3928/01477447-20090922-18 Thomas, J., & Crowhurst, T. (2013). Exertional heat stroke and susceptibility to malignant hyperthermia. Internal Medicine Journal, 43(9), 1035-1038. doi:10.1111/imi.12232

